Lockheed Martin-backed Tempo Automation sealed its reverse merger while Strand Therapeutics upped a round featuring Eli Lilly and Beigene to $97m.

Courtesy of Pexels Public markets Tempo Automation, a US-based industrial automation software provider that counts aerospace manufacturer Lockheed Martin as an investor, completed its reverse merger with special purpose acquisition company Ace Convergence Acquisition Corp and is now listed on the Nasdaq market. It agreed the $919m deal in October 2021. Funding Company nameCompany descriptionSectorCountryRoundRound…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.